HUMNYSEHospital & Medical Service PlansFiscal year ends December 31
HUMANA INC
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 29, 2026
$414.98+1.82 (+0.44%)
Close on Oct 19, 2026
- Market cap
- $50.07B
- P/E (TTM)
- 44.2
- Dividend yield
- 0.85%
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
2.1%−4.4 pts over 5 years
Net margin
0.9%−3.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +10.1% | +11.8% | +10.9% | +9.1% | |
| Operating income | +5.5% | -10.7% | -11.5% | +1.4% | |
| Net income | -1.6% | -24.9% | -18.8% | -0.7% | |
| EPS, diluted | -1.4% | -23.6% | -17.2% | +1.5% | |
| Free cash flow | -84.3% | -52.3% | -39.6% | +0.8% | |
| Dividend per share | 0.0% | +5.0% | +7.8% | +12.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 5.8% | 26.1% | 7.0% | |
| Return on assets | 2.5% | 10.5% | 2.5% | |
| Current ratio | 2.07 | 1.77 | 2.00 | |
| Debt to equity | 0.38 | 0.49 | 0.70 | |
| Net debt to EBITDA | 0.10× | – | 2.40× | |
| Interest coverage | 9.2× | 17.6× | 4.3× | |
| Capex to revenue | 1.0% | 1.2% | 0.4% | |
| Diluted shares | 151M | 133M | 121M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Humana generated $14.72B from operations and spent $11.36B on capital expenditure, dividends and share buybacks. 41% of that went back into the business.
Generated
$14.72B
Used
$11.36B
Capital expenditure$4.60B41%Dividends$2.04B18%Share buybacks$4.72B42%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin0.9%
×Asset turnover2.72×
×Equity multiplier2.80×
=Return on equity, FY20257.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 0.9% | 2.72× | 2.80× | 7.0% |
| FY2024 | 1.0% | 2.52× | 2.87× | 7.4% |
| FY2023 | 2.3% | 2.36× | 2.85× | 15.8% |
| FY2022 | 3.0% | 2.12× | 2.78× | 17.9% |
| FY2021 | 3.5% | 2.09× | 2.66× | 19.7% |
| FY2020 | 4.4% | 2.41× | 2.49× | 26.1% |
| FY2019 | 4.2% | 2.38× | 2.45× | 24.4% |
| FY2018 | 3.0% | 2.16× | 2.63× | 16.8% |
| FY2017 | 4.6% | 2.05× | 2.56× | 23.9% |
| FY2016 | 1.1% | 2.17× | 2.38× | 5.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$1.19B
- Cash generatingOperating cash flow above zero$921.00M
- Return on assets improvedROA up on the prior year2.6% → 2.6%
- Earnings backed by cashOperating cash flow above net income$921.00M vs $1.19B
- Less leverageLong-term debt to assets fell24.0% → 25.3%
- Better liquidityCurrent ratio rose1.76 → 2.00
- No dilutionShare count did not rise121M → 121M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose2.50 → 2.79